Which medication is the first-line treatment for symptomatic mild to moderate influenza infection?

Oseltamivir is the first-line treatment for symptomatic mild to moderate influenza infection primarily due to its effectiveness as a neuraminidase inhibitor. This medication works by inhibiting the enzyme neuraminidase, which is essential for the replication and release of the influenza virus from infected cells. By blocking this enzyme, oseltamivir reduces the duration and severity of flu symptoms, helping patients recover more quickly.

In cases of mild to moderate influenza, it is critical to start antiviral treatment within 48 hours of symptom onset to achieve the best results. Oseltamivir is administered orally, making it convenient for patients. Its efficacy and safety profile have made it the standard of care for treating uncomplicated influenza.

Other medications listed may also have roles in influenza treatment or management. Zanamivir, for instance, is another neuraminidase inhibitor that is administered via inhalation and can be used in similar cases; however, its usage is often limited by respiratory conditions. Remdesivir, while effective against certain viral infections like COVID-19, is not typically indicated for influenza. Baloxavir Marboxil is a newer antiviral that may also be used for influenza but is often considered when there are specific patient circumstances or resistance patterns. The widespread recommendation of